KR100767271B1 - 사퀴나비르 메실레이트 경구 투여 형태 - Google Patents
사퀴나비르 메실레이트 경구 투여 형태 Download PDFInfo
- Publication number
- KR100767271B1 KR100767271B1 KR1020067000732A KR20067000732A KR100767271B1 KR 100767271 B1 KR100767271 B1 KR 100767271B1 KR 1020067000732 A KR1020067000732 A KR 1020067000732A KR 20067000732 A KR20067000732 A KR 20067000732A KR 100767271 B1 KR100767271 B1 KR 100767271B1
- Authority
- KR
- South Korea
- Prior art keywords
- dosage form
- granules
- pharmaceutically acceptable
- saquinavir
- saquinavir mesylate
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (30)
- 메실레이트 염을 기준으로 미분된 사퀴나비르 메실레이트 60% 내지 80%, 약학적으로 허용가능한 수용성 결합제 4% 내지 8%, 약학적으로 허용가능한 붕해제 3% 내지 10%, 및 약학적으로 허용가능한 수용성 담체를 포함하는 사퀴나비르 메실레이트의 고체 단위 경구 약학 투여 제제(이때, 상기 %는 각각 약학 투여 제제의 핵 중량의 %임).
- 청구항 2은(는) 설정등록료 납부시 포기되었습니다.제 1 항에 있어서,사퀴나비르 메실레이트가 약학 투여 제제의 핵 중량의 70% 내지 75%로 존재하는 투여 제제.
- 제 1 항에 있어서,약학 투여 제제중 사퀴나비르 메실레이트가 사퀴나비르 유리 염기로서 계산시 200mg 내지 700mg의 양으로 존재하는 투여 제제.
- 청구항 4은(는) 설정등록료 납부시 포기되었습니다.제 1 항에 있어서,약학 투여 제제중 사퀴나비르 메실레이트가 사퀴나비르 유리 염기로서 계산시 250mg 내지 700mg의 양으로 존재하는 투여 제제.
- 청구항 5은(는) 설정등록료 납부시 포기되었습니다.제 1 항에 있어서,약학 투여 제제중 사퀴나비르 메실레이트가 사퀴나비르 유리 염기로서 계산시 500mg의 양으로 존재하는 투여 제제.
- 삭제
- 제 1 항에 있어서,약학적으로 허용가능한 담체가 핵 중량의 3% 내지 10%로 존재하는 투여 제제.
- 제 1 항에 있어서,약학적으로 허용가능한 담체가 30마이크론 내지 200마이크론의 입자 크기를 갖는 투여 제제.
- 제 1 항에 있어서,약학적으로 허용가능한 담체가 락토스 일수화물인 투여 제제.
- 제 9 항에 있어서,락토스 일수화물이 100마이크론 내지 150마이크론의 입자 크기를 갖는 투여 제제.
- 삭제
- 제 1 항에 있어서,약학적으로 허용가능한 수용성 결합제가 폴리비닐피롤리돈인 투여 제제.
- 삭제
- 제 1 항에 있어서,붕해제가 크로스카르멜로스 나트륨 및 크로스포비돈에서 선택되는 투여 제제.
- 제 1 항에 있어서,결정셀룰로오스를 추가로 포함하는 투여 제제.
- 제 15 항에 있어서,결정셀룰로오스가 핵 중량의 5% 내지 20%로 존재하는 투여 제제.
- 제 1 항에 있어서,투여 제제가 추가로 활택제를 포함하는 투여 제제.
- 제 17 항에 있어서,활택제가 마그네슘 스테아레이트인 투여 제제.
- 제 1 항에 있어서,약학 투여 제제의 핵이 과립 및 과립외(extra-granulation)의 혼합물로 구성되고,상기 과립이 미분된 사퀴나비르 메실레이트, 결합제, 담체 및 붕해제를 포함하고, 상기 과립외가 붕해제를 포함하고, 이때 과립중 붕해제 대 과립외중 붕해제의 비는 3:1 내지 1:1인 투여 제제.
- 제 19 항에 있어서,핵의 과립외에 포함되는 활택제를 추가로 포함하는 투여 제제.
- 제 1 항에 있어서,정제, 캡슐 및 캐플릿으로 구성된 군에서 선택된 투여 제제.
- 제 1 항에 있어서,400mg 내지 1.5g의 중량을 갖는 투여 제제.
- 삭제
- 삭제
- 삭제
- 미분된 사퀴나비르 메실레이트, 약학적으로 허용가능한 수용성 결합제, 약학적으로 허용가능한 담체 및 약학적으로 활성인 붕해제의 혼합물을 미세-과립화한 후 제분함을 포함하는, 제 1 항 내지 제 5 항중 어느 한 항, 제 7 항 내지 제 10 항중 어느 한 항, 제 12 항 또는 제 14 항 내지 제 22 항중 어느 한 항에 따른 고체 단위 경구 약학 투여 제제의 제조방법.
- 제 26 항에 있어서,(a) 단위 투여량 당 200mg 내지 800mg(유리 염기로서 계산시)의 양으로 미분된 사퀴나비르 메실레이트를 친수성 담체 및 붕해제와 함께 고 전단 과립화기중에서 혼합하는 단계;(b) 수중의 수성 결합제 용액을 단계 (a)로부터 수득된 분말 혼합물에 분무하거나 천천히 첨가하면서 혼합하여 최적 과립화 목적 지점을 달성하는 단계;(c) 단계 (b)로부터 수득된 습성 과립을 균일한 과립으로 디럼핑(delumping)하는 단계;(d) 단계 (c)로부터 수득된 습성 과립을 40℃ 내지 50℃에서 강제-공기 오븐 세트로 또는 50℃ 내지 60℃의 입구 공기 온도를 갖는 유동상 건조기로 과립의 수분 함량이 1.5 내지 2%의 범위가 될 때까지 건조하는 단계;(e) 단계 (d)로부터 수득된 건조된 과립을 제분하는 단계;(f) 단계 (e)로부터 수득된 제분된 과립을 적합한 정제 희석제와 혼합하는 단계;(g) 단계 (f)로부터 수득된 혼합물을 적합한 활택제로 활택하는 단계;(h) 단계 (g)로부터 수득된 최종 혼합물을 타정기 상에서 압착하는 단계; 및(i) 단계 (h)로부터 수득된 정제를 수성 필름 피복하는 단계를 포함하는 제조방법.
- 청구항 28은(는) 설정등록료 납부시 포기되었습니다.제 1 항 내지 제 5 항중 어느 한 항, 제 7 항 내지 제 10 항중 어느 한 항, 제 12 항 또는 제 14 항 내지 제 22 항중 어느 한 항에 있어서,치료에서 사용하기 위한 고체 단위 경구 약학 투여 제제.
- 청구항 29은(는) 설정등록료 납부시 포기되었습니다.제 1 항 내지 제 5 항중 어느 한 항, 제 7 항 내지 제 10 항중 어느 한 항, 제 12 항 또는 제 14 항 내지 제 22 항중 어느 한 항에 있어서,HIV 매개 질병의 치료에서 사용하기 위한 고체 단위 경구 약학 투여 제제.
- 삭제
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48660003P | 2003-07-11 | 2003-07-11 | |
US60/486,600 | 2003-07-11 | ||
US56820404P | 2004-05-05 | 2004-05-05 | |
US60/568,204 | 2004-05-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077016817A Division KR20070087194A (ko) | 2003-07-11 | 2004-07-05 | 사퀴나비르 메실레이트 경구 투여 형태 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060056320A KR20060056320A (ko) | 2006-05-24 |
KR100767271B1 true KR100767271B1 (ko) | 2007-10-17 |
Family
ID=34068244
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067000732A KR100767271B1 (ko) | 2003-07-11 | 2004-07-05 | 사퀴나비르 메실레이트 경구 투여 형태 |
KR1020077016817A KR20070087194A (ko) | 2003-07-11 | 2004-07-05 | 사퀴나비르 메실레이트 경구 투여 형태 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077016817A KR20070087194A (ko) | 2003-07-11 | 2004-07-05 | 사퀴나비르 메실레이트 경구 투여 형태 |
Country Status (24)
Country | Link |
---|---|
US (2) | US20050009811A1 (ko) |
EP (1) | EP1646369B1 (ko) |
JP (2) | JP4608488B2 (ko) |
KR (2) | KR100767271B1 (ko) |
AU (1) | AU2004255436B2 (ko) |
BR (1) | BRPI0412523A (ko) |
CA (1) | CA2531486C (ko) |
CO (1) | CO5640069A2 (ko) |
CR (1) | CR8172A (ko) |
EA (1) | EA015349B1 (ko) |
EC (1) | ECSP066274A (ko) |
HK (1) | HK1089959A1 (ko) |
IL (1) | IL172890A (ko) |
MA (1) | MA27904A1 (ko) |
MX (1) | MXPA06000363A (ko) |
MY (1) | MY140413A (ko) |
NO (1) | NO20060313L (ko) |
NZ (1) | NZ544585A (ko) |
PA (1) | PA8606001A1 (ko) |
PE (1) | PE20050247A1 (ko) |
RS (1) | RS20060009A (ko) |
TN (1) | TNSN06003A1 (ko) |
TW (1) | TWI356711B (ko) |
WO (1) | WO2005004836A2 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60028754T2 (de) | 1999-11-12 | 2007-05-31 | Abbott Laboratories, Abbott Park | Feste dispersion mit ritonavir, fenofibrat oder griseofulvin |
JP4608488B2 (ja) * | 2003-07-11 | 2011-01-12 | エフ.ホフマン−ラ ロシュ アーゲー | メシル酸サキナビル経口投与剤型 |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
EP2168573A1 (en) * | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
PL2851075T3 (pl) | 2012-05-14 | 2022-02-21 | Shionogi & Co., Ltd. | Preparat zawierający pochodną 6,7-nienasyconego-7-karbamoilomorfinanu |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999012527A2 (en) | 1997-09-09 | 1999-03-18 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753801A (en) * | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
EP0616841B1 (en) * | 1992-10-09 | 1998-12-23 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Production method for fine granulate |
TW390813B (en) * | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5608085A (en) * | 1995-02-27 | 1997-03-04 | The University Of Tennessee Research Corporation | Synthesis of optically active calanolides A and B and enantiomers and related compounds |
US6177460B1 (en) * | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
WO1999052504A1 (en) * | 1998-04-09 | 1999-10-21 | F. Hoffmann-La Roche Ag | Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants |
DE69915346T2 (de) * | 1998-12-17 | 2004-07-22 | Alza Corp., Mountain View | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
EP1247456A3 (en) * | 2001-02-28 | 2003-12-10 | Pfizer Products Inc. | Palatable pharmaceutical compositions for companion animals |
US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
JP4608488B2 (ja) * | 2003-07-11 | 2011-01-12 | エフ.ホフマン−ラ ロシュ アーゲー | メシル酸サキナビル経口投与剤型 |
-
2004
- 2004-07-05 JP JP2006519808A patent/JP4608488B2/ja active Active
- 2004-07-05 MX MXPA06000363A patent/MXPA06000363A/es active IP Right Grant
- 2004-07-05 AU AU2004255436A patent/AU2004255436B2/en not_active Ceased
- 2004-07-05 BR BRPI0412523-1A patent/BRPI0412523A/pt not_active IP Right Cessation
- 2004-07-05 KR KR1020067000732A patent/KR100767271B1/ko active IP Right Grant
- 2004-07-05 CA CA2531486A patent/CA2531486C/en active Active
- 2004-07-05 WO PCT/EP2004/007309 patent/WO2005004836A2/en active IP Right Grant
- 2004-07-05 RS YUP-2006/0009A patent/RS20060009A/sr unknown
- 2004-07-05 KR KR1020077016817A patent/KR20070087194A/ko not_active Application Discontinuation
- 2004-07-05 NZ NZ544585A patent/NZ544585A/en not_active IP Right Cessation
- 2004-07-05 EP EP04763093.4A patent/EP1646369B1/en active Active
- 2004-07-05 EA EA200600156A patent/EA015349B1/ru not_active IP Right Cessation
- 2004-07-07 TW TW093120382A patent/TWI356711B/zh not_active IP Right Cessation
- 2004-07-07 PE PE2004000651A patent/PE20050247A1/es not_active Application Discontinuation
- 2004-07-07 PA PA20048606001A patent/PA8606001A1/es unknown
- 2004-07-08 US US10/886,765 patent/US20050009811A1/en not_active Abandoned
- 2004-07-09 MY MYPI20042754A patent/MY140413A/en unknown
-
2005
- 2005-12-29 IL IL172890A patent/IL172890A/en not_active IP Right Cessation
-
2006
- 2006-01-05 CR CR8172A patent/CR8172A/es unknown
- 2006-01-06 CO CO06001295A patent/CO5640069A2/es not_active Application Discontinuation
- 2006-01-06 MA MA28709A patent/MA27904A1/fr unknown
- 2006-01-06 TN TNP2006000003A patent/TNSN06003A1/en unknown
- 2006-01-09 EC EC2006006274A patent/ECSP066274A/es unknown
- 2006-01-20 NO NO20060313A patent/NO20060313L/no not_active Application Discontinuation
- 2006-09-25 HK HK06110649.8A patent/HK1089959A1/xx unknown
-
2008
- 2008-10-31 US US12/262,607 patent/US20090054481A1/en not_active Abandoned
-
2010
- 2010-08-13 JP JP2010181350A patent/JP2010280707A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
WO1999012527A2 (en) | 1997-09-09 | 1999-03-18 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021167343A (ja) | パルボシクリブの固形剤形 | |
JP4101661B2 (ja) | 非晶質メシル酸ネルフィナビルの製薬剤形 | |
NL1021857C2 (nl) | Tamsulosinetabletten met een gewijzigde vrijgave. | |
ES2205000T3 (es) | Composicion farmaceutica que contiene irbesartan. | |
RU2733410C2 (ru) | Лекарственные формы цитрата железа (iii) | |
US7976869B2 (en) | Fenofibrate tablets | |
JP2007224041A (ja) | 医薬組成物 | |
CN102655752A (zh) | 包含整合酶抑制剂的固体药物组合物 | |
JP5000504B2 (ja) | トラネキサム酸製剤 | |
US20090054481A1 (en) | Saquinavir Mesylate Oral Dosage Form | |
EP0425298B1 (en) | Sustained-release preparation of basic medical agent hydrochloride | |
EP1315480B1 (en) | "slow release" pharmaceutical compositions comprising lithium carbonate | |
JP2939069B2 (ja) | ニカルジピン持続性製剤とその製造方法 | |
EP0906754B1 (en) | Rapid-release s1452 tablets | |
WO2019008426A1 (en) | NOVEL ENZALUTAMIDE ORAL GALENIC FORM COMPOSITION AND METHOD OF MANUFACTURING THE SAME | |
CN1822822B (zh) | 甲磺酸沙喹那韦口服剂型 | |
AU2002319154B2 (en) | Pharmaceutical dosage form of amorphous nelfinavir mesylate | |
CA2709624A1 (en) | Immediate release dosage form of bosentan and process of manufacturing such | |
KR20160034351A (ko) | 리팜피신, 이소니아지드, 에탐부톨 및 피라진아미드를 포함하는 항결핵 조성물 및 그의 제조 방법 | |
AU2002319154A1 (en) | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20120927 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130927 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140929 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160929 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180928 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190924 Year of fee payment: 13 |